Neutralization Assay Using a Modified Vaccinia Virus Ankara Vector Expressing the Green Fluorescent Protein Is a High-Throughput Method to Monitor the Humoral Immune Response against Vaccinia Virus

Clinical and Diagnostic Laboratory Immunology

Volumn 11, Issue 2, 2004, Pages 406-410

  Cosma, Antonio ^a   Bühler, Silja ^b   Nagaraj, Rashmi ^a   Staib, Caroline ^b   Hammarin, Anna Lena ^d   Wahren, Britta ^d   Goebel, Frank D ^c   Erfle, Volker ^a,b   Sutter, Gerd ^a,b  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GREEN FLUORESCENT PROTEIN; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; BIOLOGICAL WARFARE; CONTROLLED STUDY; EXPRESSION VECTOR; GENETIC ENGINEERING; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOLOGICAL MONITORING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMALLPOX; TERRORISM; VACCINATION; VACCINIA VIRUS; VACCINIA VIRUS ANKARA VECTOR; VIRUS IMMUNITY; VIRUS NEUTRALIZATION;

ANIMALS; ANTIBODIES, VIRAL; ANTIBODY FORMATION; ANTIBODY SPECIFICITY; B-LYMPHOCYTES; CELL LINE; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HUMANS; LUMINESCENT PROTEINS; MICE; NEUTRALIZATION TESTS; RABBITS; VACCINIA; VACCINIA VIRUS;

EID: 12144290997     PISSN: 1071412X     EISSN: None     Source Type: Journal    
DOI: 10.1128/CDLI.11.2.406-410.2004     Document Type: Article

References (19)

1. Cosma, A., R. Nagaraj, S. Bühler, J. Hinkula, D. H. Busch, G. Sutter, F. D. Goebel, and V. Erfle. 2003. Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals. Vaccine 22:21-29.
2. Drexler, I., E. Antunes, M. Schmitz, T. Wolfel, C. Huber, V. Erfle, P. Rieber, M. Theobald, and G. Sutter. 1999. Modified vaccinia virus Ankara for delivery of human tyrosinase as melanoma-associated antigen: induction of tyrosinase- and melanoma-specific human leukocyte antigen A* 0201-restricted cytotoxic T cells in vitro and in vivo. Cancer Res. 59:4955-4963.
3. Drexler, I., K. Heller, B. Wahren, V. Erfle, and G. Sutter. 1998. Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J. Gen. Virol. 79:347-352.
4. Geretti, A. M., M. E. Dings, C. A. van Els, C. A. van Baalen, F. J. Wijnholds, J. C. Borleffs, and A. D. Osterhaus. 1996. Human immunodeficiency virus type 1 (HIV-1)-and Epstein-Barr virus-specific cytotoxic T lymphocyte precursors exhibit different kinetics in HIV-1-infected persons. J. Infect. Dis. 174:34-45.
5. Goldstein, J. A., J. M. Neff, J. M. Lane, and J. P. Koplan. 1975. Smallpox vaccination reactions, prophylaxis, and therapy of complications. Pediatrics 55:342-347.
6. Hirsch, V. M., T. R. Fuerst, G. Sutter, M. W. Carroll, L. C. Yang, S. Goldstein, M. Piatak, Jr., W. R. Elkins, W. G. Alvord, D. C. Montefiori, B. Moss, and J. D. Lifson. 1996. Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. J. Virol. 70:3741-3752.
7. Katz, J. B. 1987. The effect of the virus-serum incubation period upon vaccinia virus serum neutralization titers. J. Biol. Stand. 15:389-392.
8. Kohleisen, B., M. Neumann, R. Herrmann, R. Brack-Werner, K. J. Krohn, V. Ovod, A. Ranki, and V. Erfle. 1992. Cellular localization of Nef expressed in persistently HIV-1-infected low-producer astrocytes. AIDS 6:1427-1436.
9. Law, M., and G. L. Smith. 2001. Antibody neutralization of the extracellular enveloped form of vaccinia virus. Virology 280:132-142.
10. Lennette, E. H., and N. J. Schmidt (ed.). 1979. Diagnostic procedures for viral, rickettsial and chlamydial infections, 5th ed., vol. 10, p. 257-308. American Public Health Association, Washington, D.C.
11. Manischewitz, J., L. R. King, N. A. Bleckwenn, J. Shiloach, R. Taffs, M. Merchlinsky, N. Eller, M. G. Mikolajczyk, D. J. Clanton, T. Monath, R. A. Weltzin, D. E. Scott, and H. Golding. 2003. Development of a novel vaccinia-neutralization assay based on reporter-gene expression. J. Infect. Dis. 188: 440-448.
12. Moss, B. 1996. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc. Natl. Acad. Sci. USA 93:11341-11348.
13. Moss, B., and P. L. Earl. 1991. Expression of proteins in mammalian cells using vaccinia viral vectors, p. 16.16.1-16.16.7. In F. M. Ausubel, R. Brent, R. Kingston, D. Moore, J. Seidman, J. Smith, and K. Struhl (ed.), Current protocols in molecular biology. Wiley, New York, N.Y.
14. Ramirez, J. C., M. M. Gherardi, D. Rodriguez, and M. Esteban. 2000. Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of preexisting immunity to the vector. J. Virol. 74: 7651-7655.
15. Smith, G. L., A. Vanderplasschen, and M. Law. 2002. The formation and function of extracellular enveloped vaccinia virus. J. Gen. Virol. 83:2915-2931.
16. Staib, C., I. Drexler, M. Ohlmann, S. Wintersperger, V. Erfle, and G. Sutter. 2000. Transient host range selection for genetic engineering of modified vaccinia virus Ankara. BioTechniques 28:1137-1148.
17. Stienlauf, S., M. Shoresh, A. Solomon, T. Lublin-Tennenbaum, Y. Atsmon, Y. Meirovich, and E. Katz. 1999. Kinetics of formation of neutralizing antibodies against vaccinia virus following re-vaccination. Vaccine 17:201-204.
18. Sutter, G., and B. Moss. 1992. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl. Acad. Sci. USA 89:10847-10851.
19. Yang, Z. Y., L. S. Wyatt, W. P. Kong, Z. Moodie, B. Moss, and G. J. Nabel. 2003. Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J. Virol. 77:799-803.